Medical Device Traceability Matrix: Guide

Reviewed September 17, 2026

A traceability matrix is often the first document a reviewer opens because it shows, in one place, whether a manufacturer's cybersecurity claims hold together. When a threat model identifies a risk but no requirement addresses it, or a requirement exists but no test verifies it, the gap is visible immediately and becomes the basis for an Additional Information request. That gap can add months to a clearance timeline and, worse, can mean a real vulnerability shipped unaddressed. Building the matrix after the fact, once engineering is finished and the submission is due, is where most manufacturers lose time, because reconstructing which control addressed which threat requires re-interviewing engineers and re-reading old design documents. A traceability matrix maintained from the start of development, alongside the ISO 14971 risk file and IEC 62304 software requirements, turns this from a submission burden into a routine engineering output.

Why This Matters

The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (February 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. The guidance expects manufacturers to show a clear linkage between identified risks, the controls implemented to address them, and the testing that verified those controls, which is exactly what a traceability matrix documents.

Reviewers apply this expectation the same way they apply software lifecycle requirements from IEC 62304, which requires traceability between software requirements, design, and verification, and risk management requirements from ISO 14971, which requires traceability between hazards, risk controls, and verification of control effectiveness. A cybersecurity traceability matrix is not a separate obligation; it is the security-specific extension of traceability practices manufacturers already maintain for safety and software quality.

The FDA's FY2025 MDUFA Performance Report lists cybersecurity among the subject-matter expert areas that may be involved in reviewing a device submission, alongside sterility, biocompatibility and software. A large share of those deficiencies trace back to gaps a matrix would have surfaced early: a threat identified in a model with no corresponding requirement, or a requirement with no verification evidence attached. Treating traceability as a checklist assembled at submission time, rather than a design-controlled engineering artifact maintained throughout development, is what creates that gap.

What Does a Cybersecurity Traceability Matrix Actually Link?

A cybersecurity traceability matrix links five things in sequence: the threat identified during threat modeling, the security risk it creates, the requirement written to address it, the control implemented to satisfy the requirement, and the verification evidence proving the control works. Each row of the matrix represents one complete chain from threat to proof.

Skipping a link in that chain is the most common failure mode. A threat model might identify a risk of unauthorized firmware modification, but if no requirement explicitly states the control (such as cryptographic signature verification before installation), the risk exists without a documented answer. Conversely, a requirement without a verification result is just a claim; reviewers expect a test report, not a statement of intent.

What Should an Example Traceability Matrix Look Like?

An example traceability matrix has one row per threat and columns for the threat, the risk it creates, the requirement addressing it, the control implemented, and the verification evidence produced. The table below shows the pattern using common medical device threats.

Each row should also record the residual risk after the control is applied and a reference to where that residual risk is accepted in the ISO 14971 risk management file, since some risk always remains even after a control is implemented.

How Does the Matrix Tie Into ISO 14971 Risk Controls?

The traceability matrix ties into ISO 14971 by mapping each cybersecurity threat to the same risk analysis, risk evaluation, and risk control structure the standard already requires for safety hazards. ISO 14971 requires that every identified hazard link to a risk control and that the effectiveness of that control be verified, and a cybersecurity threat is treated as a hazard-generating event within that same framework.

The practical connection is that a security threat's clinical impact, such as a device malfunction from a manipulated command or a patient safety event from corrupted telemetry, needs a severity and probability rating consistent with the same risk matrix used for other hazards in the file. The traceability matrix then becomes the mechanism that shows the risk control (a cybersecurity control) was actually implemented and verified, closing the loop that ISO 14971 requires between hazard identification and control effectiveness.

How Does the Matrix Tie Into IEC 62304 Software Requirements?

See also: How SPDF Maps to IEC 81001-5-1 Activities, IEC 81001-5-1 vs IEC 62304 for Medical Devices, and JSP2 vs SPDF vs IEC 81001-5-1: Framework Pick.

The traceability matrix ties into IEC 62304 by treating each security requirement as a software requirement subject to the same design, implementation, and verification traceability the standard mandates for all software requirements. IEC 62304 requires bidirectional traceability from software requirements through software design to verification, and security requirements are not exempt from that expectation just because they originate from a threat model rather than a functional specification.

In practice, this means a security requirement like "all database access must use parameterized queries" needs the same lifecycle documentation as a functional requirement: it appears in the software requirements specification, maps to a design element in the architecture, and links to a specific verification activity such as a SAST rule or a targeted penetration test case. Software of unknown provenance and third-party components add another dimension, since a vulnerability in an SBOM-tracked component needs to trace to the requirement it violates and the mitigation applied.

What Do Reviewers Look For in a Traceability Matrix?

Reviewers look for completeness, consistency, and evidence that verification actually happened rather than being described in future tense. A matrix that lists controls as "planned" or "to be implemented" signals that the submission is premature, since the FDA's guidance expects controls to be implemented and verified before submission, not scheduled.

Reviewers also check for consistency between the matrix and the other submission artifacts: the threat model, the SBOM, the penetration test report, and the risk management file all need to reference the same threats and controls using consistent terminology. A mismatch, such as a threat named differently in the threat model than in the matrix, creates friction and invites additional questions even when the underlying engineering is sound.

Finally, reviewers look for evidence the matrix is a living document rather than a one-time submission artifact. A postmarket vulnerability disclosure process that references the same matrix to identify affected requirements and components demonstrates that traceability supports the full product lifecycle, not just the initial clearance.

How Blue Goat Cyber Approaches This

Blue Goat Cyber builds traceability matrices as part of the engineering process, not as a document assembled after testing is complete. We start from the threat model, carry each threat through its ISO 14971 risk entry and IEC 62304 requirement, and link it to the specific verification evidence, whether that's a SAST finding, a penetration test result, or an SBOM-linked vulnerability assessment.

Our medical device threat modeling services establish the threat inventory that becomes the first column of the matrix, and our FDA premarket cybersecurity services carry that inventory through to a submission-ready matrix that stays consistent with the risk file and software requirements specification. We build the matrix so it can be maintained after clearance, supporting postmarket vulnerability response without starting from scratch.

Frequently Asked Questions

Why does a traceability matrix matter for FDA premarket review?

The FDA's February 3, 2026 final guidance expects a documented, consistent link between identified cybersecurity risks, the controls that address them, and the verification evidence proving those controls work. A traceability matrix is how manufacturers demonstrate that linkage in one place, and its absence or incompleteness is a common driver of Additional Information requests.

What columns should a cybersecurity traceability matrix include?

At minimum, a matrix should include the identified threat, the resulting security risk, the requirement written to address it, the control implemented, and the verification evidence produced. Many manufacturers add a residual risk column and a reference to where that risk is accepted in the ISO 14971 risk management file.

How does traceability support postmarket vulnerability management?

When a new vulnerability is disclosed, the matrix lets a manufacturer quickly identify which requirements, controls, and components are affected without re-analyzing the entire system from scratch. This supports the kind of rapid impact assessment expected under postmarket cybersecurity management practices.

Is a traceability matrix only necessary for software-heavy devices?

No. Any device with cybersecurity risk exposure, including hardware with firmware, wireless interfaces, or network connectivity, needs traceability from threats through to verification. The matrix scope should match the device's actual attack surface, not its software complexity.

When should the traceability matrix be built?

It should be built incrementally starting with the initial threat model, not assembled right before submission. Building it alongside development means each requirement and control already has its verification evidence attached by the time the submission package is compiled.

CTA

If you need help building a traceability matrix that holds up under FDA review and stays usable after clearance, we can help you connect your threat model, risk file, and verification evidence into one consistent chain.

Book a Discovery Session